The challenge stems from the nature of TCR recognition itself. Naturally occurring TCRs often bind tumor antigens with suboptimal affinity, and simply boosting binding strength can backfire, reducing specificity and raising the risk of off-target attacks on healthy tissue. Affinity enhancement strategies have historically produced receptors that cross-react with unrelated peptides, a potentially lethal side effect. Writing in Frontiers in Chemical Biology, Mario Frezzini and Daniele Narzi argue that the field needs more than raw computational power; it needs mechanistic understanding, a way of knowing not just which receptor variants bind well, but why they bind well and what molecular consequences each mutation carries.

Artificial intelligence has transformed the search for better TCRs in recent years. Deep learning models can explore vast stretches of TCR sequence space, predicting which amino acid sequences are compatible with a desired structural framework and generating libraries of candidate variants in silico. Structure-based deep learning approaches have shown genuine promise in proposing receptor variants with improved binding properties. But these tools, the authors contend, are largely data-driven and descriptive: they rely on static structural representations and scoring functions that fail to capture the dynamic, ever-fluctuating nature of protein-protein interactions. The result is an embarrassment of riches—thousands of candidates that are difficult to prioritize, and little insight into the physical determinants of recognition.

Molecular dynamics simulations sit at the opposite end of the spectrum. By explicitly modeling every atom of a TCR-peptide-MHC complex as it jiggles, flexes, and interacts in a simulated watery environment, MD reveals conformational plasticity, residue-specific energetic contributions, and the cooperative behavior of the binding interface. Decades of simulation work have shown that TCR recognition is anything but a rigid lock-and-key event; the complementarity-determining regions, the receptor’s antigen-grasping loops, fluctuate significantly, contributing to both adaptability and specificity. The catch is computational cost. Reliable MD characterization demands all-atom simulations under physiological conditions, roughly ten independent replicas per system, and sampling times of at least hundreds of nanoseconds per replica to reach statistical convergence. That makes MD suitable for analyzing only a few tens of closely related variants, not for screening hundreds of candidates.

Rather than viewing these limitations as weaknesses, Frezzini and Narzi propose exploiting them deliberately. In their framework, MD is positioned as a low-throughput, high-information filter—a step that examines a carefully chosen handful of candidates in exquisite detail. The pipeline begins with biologically grounded receptor selection: repertoire sequencing of tumor-infiltrating lymphocytes, peripheral blood, or antigen-specific T cell populations, combined with bioinformatic analysis of clonal expansion, persistence, and CDR3 sequence similarity, identifies candidate receptors with known or putative tumor reactivity. AI-driven design then explores the local sequence space around these validated scaffolds, generating variant libraries. Fast pre-screening tools—empirical scoring functions, rapid energetic estimates, or machine learning predictors—trim the candidate pool to a manageable size before the expensive physics-based refinement begins.

At the heart of the workflow, MD serves as an integrative mechanistic engine rather than a brute-force screener. Trajectory analyses quantify how flexibly the CDR loops move, which interaction patterns stabilize the complex over time, and, through residue-specific energy decomposition schemes, which individual amino acids contribute favorably to binding. Crucially, the simulations also map allosteric communication pathways—networks of dynamically coupled residues that connect the binding interface to distal regions of the receptor. Local perturbations can propagate through the structure and modulate the behavior of residues tens of angstroms away, meaning that mutations in one part of the receptor can reshape binding chemistry at another. This dual description of energetics and allostery gives the pipeline a mechanistic criterion for prioritizing variants that goes far beyond static sequence-based metrics.

The power of this approach is illustrated by the authors’ own recent computational work on a pair of closely related engineered TCRs, c796 and its parent c728. The two receptors differ by a single conservative mutation, E31D, in the CDR1 loop, yet experiments show the variant binds its target peptide-MHC complex roughly six-fold more tightly. Counterintuitively, detailed energetic analysis revealed that the mutated residue itself contributes nothing directly to the improved affinity. Instead, the single substitution triggers a redistribution of interaction energies across multiple residues, including positions in distal CDR loops that now stabilize the interface more favorably. Network analyses of simulation trajectories traced allosteric pathways linking the mutation site to these distant regions. In other words, binding affinity in TCR systems emerges from a cooperative web of interactions, and even a minimal sequence change can produce substantial functional consequences through dynamic, long-range mechanisms—precisely the kind of hidden logic that only MD-based mechanistic analysis can expose.

The framework’s final stage returns to the laboratory, where two complementary experimental technologies validate the computationally refined candidates. Surface plasmon resonance, the gold standard for biophysical characterization, directly measures the association and dissociation rates of TCR-peptide-MHC binding, providing quantitative affinity and kinetic parameters for a limited set of high-confidence variants. But SPR requires recombinant protein expression and purification, offers relatively low throughput, and cannot capture the conformational and energetic complexity that governs T cell activation. That gap is filled by cellular reporter assays such as RAPTR, which evaluate TCR activation in response to specific peptide-MHC complexes within a living cellular environment, capturing downstream signaling and functional output at higher throughput. Importantly, binding affinity alone does not necessarily correlate with functional efficacy, so these orthogonal layers of validation—molecular binding on one side, cellular function on the other—are essential for identifying receptors that are both strong and clinically useful.

What distinguishes the proposed strategy from previous pipelines is its iterative, bidirectional character. Energetic fingerprints and allosteric maps derived from MD are fed back into the AI design models, narrowing and sharpening the sequence space they explore in the next round. Experimental results, in turn, benchmark and improve the computational predictions. The authors describe this as a closed-loop, multi-scale design paradigm, building on recent demonstrations that lab-in-the-loop AI-guided optimization can work for therapeutic antibody engineering. Emerging generative tools such as AlphaFlow and BioEmu may eventually accelerate conformational sampling upstream, and the authors envision hybrid strategies in which AI-generated structural ensembles initialize diverse conformations for explicit-solvent MD refinement—though they caution that these newer methods have not yet been validated for multichain TCR-peptide-MHC complexes or mutation-induced energy changes.

The approach is not without caveats. MD-based mechanistic insight is only as reliable as the structural model underlying the simulations, and accurate models of TCR-peptide-MHC complexes remain challenging to obtain because of the intrinsic flexibility of the CDR loops and the complexity of protein-protein recognition. AI tools like AlphaFold have improved structural prediction enormously, but performance for receptor-ligand complexes is still limited without experimental structural data. The authors therefore stress that every mechanistic hypothesis generated in silico must be experimentally validated before guiding the next round of optimization. If the framework delivers on its promise, however, the payoff could be substantial: a scalable, adaptive design engine that unifies statistical learning with physical principles, capable of producing the high-affinity, exquisitely specific, and safe T cell receptors that next-generation cancer immunotherapy demands. The convergence of AI, molecular dynamics, and experimental validation may finally turn TCR engineering from an empirical art into a predictive science.

Subject of Research: Integrating artificial intelligence, molecular dynamics simulations, and experimental assays for mechanism-aware engineering of T cell receptors in cancer immunotherapy

Article Title: Bridging AI, molecular dynamics, and experiments for mechanism-aware TCR engineering in cancer immunotherapy

Article References: Frezzini, M., & Narzi, D. (2026). Bridging AI, molecular dynamics, and experiments for mechanism-aware TCR engineering in cancer immunotherapy. Frontiers in Chemical Biology, 5, Article 1909618. https://doi.org/10.3389/fchbi.2026.1909618

Image Credits: AI Generated

DOI: 10.3389/fchbi.2026.1909618

Keywords: T cell receptor engineering, cancer immunotherapy, artificial intelligence, molecular dynamics simulations, allosteric communication, peptide-MHC complex, surface plasmon resonance, RAPTR assay, protein design, adoptive T cell therapy, binding affinity, computational biology

The core idea is deceptively simple. Natural T cells do not rely on their antigen receptor alone; they depend on co-stimulatory receptors such as CD28 and ICOS, the inducible T cell co-stimulator, to fine-tune activation, survival and differentiation. The researchers reasoned that if a therapeutic T cell receptor could be fused directly to a co-stimulatory signaling domain, every encounter with a tumor cell would deliver not just a recognition signal but a survival and persistence signal at the same time. The construct they engineered, which they call TCR:ICOS, combines the extracellular variable and constant domains of a conventional T cell receptor with a CD28 transmembrane segment and intracellular domains drawn from both ICOS and CD3 epsilon. The result is a single hybrid receptor that couples antigen specificity to co-stimulation in one molecular unit.

The functional consequences in mice were dramatic. T cells carrying the TCR:ICOS receptor showed enhanced, antigen-specific production of inflammatory cytokines, the chemical weapons that help recruit and coordinate an immune attack. More importantly, the cells persisted far longer within tumors than their conventional counterparts, and this persistence translated into clinical outcomes: delayed recurrence of melanoma and, in a subset of animals, complete and durable cures. For a field in which the transience of engineered T cells is a central bottleneck, the demonstration that a receptor-level modification can extend the working lifespan of the cells inside a hostile tumor microenvironment is a significant proof of concept.

Beneath the phenotypic changes lies a defined signaling logic. The team found that TCR:ICOS activation engaged two major pathways, PI3K and NF-kappa B, while paradoxically restraining the activation of AKT, a kinase downstream of PI3K that is often associated with terminal differentiation and metabolic burnout in T cells. This combination appears to be the key to the durability. Sustained PI3K and NF-kappa B signaling supports inflammatory function and survival, while blunted AKT activity helps the cells avoid the hyperactive, exhausted state that typically shortens the life of tumor-infiltrating lymphocytes. When the researchers genetically ablated the ICOS-PI3K pathway, the long-term anti-tumor effects disappeared, confirming that this signaling axis is not a side effect but the mechanistic engine of the durable response.

Single-cell level analysis reinforced the picture of a fundamentally altered differentiation program. TCR:ICOS T cells were enriched for a stem-like state, a less differentiated, self-renewing condition that immunologists regard as the hallmark of long-lived, re-challenge-capable T cell populations. They also showed resistance to exhaustion, the progressive loss of function marked by inhibitory receptors such as PD1, LAG3 and TIM3 that plagues conventional tumor-infiltrating cells. In practical terms, the engineered cells behaved less like short-lived commandos and more like a renewable garrison, capable of maintaining pressure on the tumor over time rather than expending themselves in a single burst of activity.

Translating the concept from mouse to human T cells required an additional round of molecular engineering. Early versions of the hybrid receptor did not express efficiently on the surface of human cells, a common obstacle in receptor design where folding, assembly and trafficking can fail silently. The team solved this by identifying a single amino acid change in the cytosolic tail of the receptor that enabled functional surface expression. Crucially, the optimized receptor avoided two well-known hazards of introducing engineered T cell receptors into patient cells: mispairing with endogenous TCR chains, which can create unpredictable and potentially dangerous specificities, and competition for limited CD3 molecules, which can impair the function of the T cell’s native receptor complex.

The human-cell experiments went beyond a single antigen. The researchers showed that the optimized TCR:ICOS format sustained the functional performance of human T cells across repeated stimulation cycles and could be extended to multiple tumor antigens, including targets relevant to solid cancers such as NY-ESO-1 and ROPN1, without eroding T cell fitness. This uniform applicability matters for the field. Many receptor-engineering advances are idiosyncratic, working for one TCR or one antigen but failing when generalized. A format that preserves T cell quality across different specificities offers a modular platform: any tumor-reactive TCR could, in principle, be equipped with the same built-in co-stimulation and inherit the same durability advantages.

The findings arrive at a moment when the cell therapy field is intensely focused on next-generation designs. Chimeric antigen receptors, or CARs, already incorporate co-stimulatory domains such as CD28 or 4-1BB, and that choice profoundly shapes how CAR T cells persist and differentiate. TCR-based therapies, which can recognize intracellular tumor antigens presented by HLA molecules and therefore access a much larger pool of cancer targets, have lacked an equivalent, systematic way to embed co-stimulation. The TCR:ICOS design fills that gap, and its mechanism, favoring stem-like persistence through PI3K and NF-kappa B while restraining AKT, offers a template that other groups can rationally modify.

There are, of course, steps between a mouse melanoma model and approved therapy. The study was conducted in preclinical systems, and human trials will need to establish safety, particularly given that engineered co-stimulation could, in principle, amplify off-tumor reactivity if a TCR recognizes healthy tissue. Dosing, manufacturing consistency and the behavior of TCR:ICOS cells in the complex, immunosuppressive environment of human solid tumors all remain to be tested. The authors note that the work was supported by the Dutch Cancer Society and a Health Holland public-private partnership, and several team members report pending patents related to the receptor design, signaling commercial interest in bringing the platform toward clinical evaluation.

Even so, the study offers a compelling answer to one of adoptive cell therapy’s most persistent questions: how to make engineered T cells last. By fusing recognition and co-stimulation into a single receptor, the Rotterdam team has shown that durability can be designed into the therapeutic product itself rather than bolted on with cytokines, checkpoint blockade or lymphodepleting chemotherapy. If the format performs in human trials as it has in mice, TCR:ICOS could become a foundational component of fitter, longer-lived T cell products for solid tumors, turning a transient spark of immune attack into a sustained campaign against cancer.

Subject of Research: Engineering T cell receptors with built-in ICOS co-stimulation to extend the durability of adoptive T cell therapy against solid tumors

Article Title: T cell receptors equipped with ICOS provide T cells with durable anti-tumor response

Article References: Marraffa, A., Berrevoets, C., Mosiello, M., Coelho, R. M., Roelofs, D., van Brakel, M., Wijers, R., Kroese, K., Peeters, M. J., Dik, W. A., Kunert, A., Abbott, R. J., Hammerl, D., Schliehe, C., & Debets, R. (2026). T cell receptors equipped with ICOS provide T cells with durable anti-tumor response. Molecular Cancer, 25(1), Article 216. https://doi.org/10.1186/s12943-026-02765-9

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02765-9

Keywords: adoptive T cell therapy, T cell receptor, ICOS, co-stimulation, T cell exhaustion, solid tumors, melanoma, PI3K signaling, NF-kappa B, stem-like T cells, gene engineering, Molecular Cancer

The study began with a practical problem: researchers have lacked good tools to study the behavior of hepatitis B virus-specific T cells in a physiologically relevant setting. The team used a humanized mouse model carrying the human HLA-A11 molecule to identify a T cell receptor that recognizes HBc141-151, an epitope from the hepatitis B core antigen that is clinically relevant in human patients. This receptor, which the authors call HB-I, allowed them to generate transgenic mice whose entire CD8+ T cell population is specific for a single, human-relevant HBV epitope, providing a tractable platform for dissecting why these cells fail during chronic infection.

With that platform in hand, the researchers turned to an unbiased discovery strategy. Using a whole-genome CRISPR-Cas9 knockout library delivered into HBV-specific T cells, followed by screening under chronic antigen stimulation, they asked which genes, when deleted, would help T cells resist the dysfunctional state that normally develops. The screen converged on Ankrd11, a gene previously known as a chromatin regulator implicated in neural development and in Kabuki-like syndromes, but never before linked to T cell exhaustion. Loss of Ankrd11 consistently produced T cells that proliferated more vigorously and retained stronger effector characteristics.

The mechanistic picture that emerges from the paper is epigenetic. ANKRD11 appears to restrain the accessibility and acetylation of key effector genes. Using ATAC-seq, bulk RNA-seq and CUT&Tag profiling of the histone mark H3K27ac, the team showed that Ankrd11-deficient CD8+ T cells display increased chromatin openness and enhancer acetylation at loci encoding AP-1 family transcription factors, notably Fos and Fosb. Elevated AP-1 activity, in turn, drives a program of effector differentiation: the cells produce more granzyme B and interferon-gamma, resist the immunosuppressive conditions that normally silence them, and maintain function even when interleukin-2, a survival factor, is limiting.

Functionally, the consequences of losing this brake were striking. In mice carrying a replicating HBV plasmid or infected with recombinant HBV vectors, Ankrd11-deficient HBV-specific T cells expanded more robustly, infiltrated the liver more effectively, and drastically reduced serum levels of hepatitis B surface antigen, viral DNA and markers of liver damage. Parallel experiments using a second chronic infection model, lymphocytic choriomeningitis virus clone 13, confirmed the generality of the effect: adoptively transferred Ankrd11-deficient virus-specific P14 T cells showed enhanced granzyme expression, proliferation and viral control in the spleen and blood.

Perhaps the most conceptually interesting finding concerns the differentiation paths that exhausted T cells normally follow. In chronic infection and cancer, antigen-specific CD8+ T cells split into progenitor exhausted T cells, which express the transcription factor TCF-1 and serve as a self-renewing reservoir, and terminally exhausted T cells, which lose TCF-1 and are irreversibly dysfunctional. The authors found that Ankrd11 deficiency accelerates the conversion of progenitor exhausted cells into effector-like exhausted cells, but importantly, the resulting cells are cytotoxic and functional rather than inert. This suggests ANKRD11 does not simply maintain progenitor pools but actively gates how far exhausted cells differentiate toward effector competence.

The study also revealed a distinct route of reprogramming specific to chronic hepatitis B. A large fraction of HBV-specific CD8+ T cells in tolerant mice carries a PD-1-negative, TOX-negative phenotype that has resisted conventional checkpoint-based rescue strategies. When ANKRD11-mediated repression was relieved, these tolerant cells differentiated into PD-1-positive, KLRG1-positive effector cells armed with high granzyme levels, providing an explanation for the improved viral clearance. In other words, ANKRD11 deficiency unlocks an otherwise dormant pool of virus-specific cells that immune checkpoint blockade alone cannot reach.

The antitumor implications were tested directly in cancer models. Ankrd11-deficient CD8+ T cells promoted rejection of implanted tumors, enhanced intratumoral T cell activity, and acted synergistically with immune checkpoint blockade, potentiating the effect of PD-1 pathway inhibition. Given that the exhaustion of tumor-infiltrating lymphocytes is a central cause of immunotherapy failure, a single gene whose deletion reprograms effector differentiation under immunosuppressive conditions is an attractive candidate for therapeutic engineering, for example in chimeric antigen receptor or T cell receptor-engineered cell products. A provisional patent application has been filed based on the findings, underscoring the translational interest.

Caveats remain before ANKRD11 targeting reaches the clinic. ANKRD11 is a broad chromatin regulator with established roles in neural and cardiac development, so systemic inhibition is unlikely to be safe; the therapeutic window will probably lie in ex vivo engineering of T cells or in carefully targeted delivery. It will also be important to determine whether accelerated terminal differentiation comes at the cost of long-term memory formation. Nevertheless, the study delivers a clear conceptual advance: T cell dysfunction in chronic infection and cancer is not merely the product of inhibitory receptor signaling, but is epigenetically authored, and specific chromatin factors such as ANKRD11 can be removed to rewrite that script. For the hundreds of millions of people living with chronic hepatitis B, and for cancer patients whose T cells have gone quiet, that insight opens a new direction for immunotherapy design.

The concept of T cell exhaustion has shaped immunology for two decades. Since the landmark demonstration that chronically stimulated CD8+ T cells can regain function when inhibitory pathways are interrupted, researchers have catalogued a molecular signature of the dysfunctional state, and later work established the transcription factor TOX as a master architect of the exhaustion program, acting at both transcriptional and epigenetic levels. What has remained less clear is whether exhaustion is a fixed fate or a tunable state whose chromatin underpinnings can be deliberately rewritten. The new study adds weight to the second view by identifying a specific chromatin-associated protein whose removal shifts the balance of differentiation toward cytotoxic competence.

The methodological route to this finding is worth noting. Genome-wide CRISPR-Cas9 knockout screens have become a powerful way to uncover genes that constrain or enable T cell behavior, and previous efforts using this approach identified regulators such as REGNASE-1 and Roquin as suppressors of effector expansion and antitumor immunity. The present screen extends this logic into the setting of chronic hepatitis B virus infection, a context in which suppressive cues differ from those in tumors and in which conventional checkpoint blockade has shown only modest clinical benefit. That an unbiased screen converged on a gene with no prior immunological pedigree illustrates how phenotype-first discovery can bypass assumptions rooted in known pathways.

ANKRD11 itself carries an interesting dual history. It was first characterized as a chromatin regulator essential for neural development, and subsequent work showed it controls cardiac neural crest-mediated remodeling of the outflow tract. Its association with a Kabuki-like syndrome in humans reflects the pleiotropic consequences of disturbing a factor that operates broadly across tissues. This background both explains why the protein had escaped attention in immunology and reinforces the caution that any therapeutic interference must be confined to engineered cells rather than delivered systemically.

The AP-1 connection provides a mechanistic bridge to earlier T cell biology. AP-1 family transcription factors, built from Fos and Jun proteins, have long been recognized as immediate-early responders to T cell receptor signaling, and their activity is known to cooperate with other factors to specify effector genes. By showing that ANKRD11 restrains chromatin accessibility and H3K27 acetylation at AP-1 loci, the study suggests a route by which a chromatin regulator can gate a transcriptional program that is otherwise primed and waiting in naive and exhausted cells alike.

The authors have deposited the datasets underlying these conclusions in public repositories: bulk RNA-seq data under accession GSE299520, ATAC-seq data under GSE299519, and CUT&Tag data under GSE299521, with source data provided alongside the paper. No original code was generated. This transparency should allow groups working on T cell engineering to interrogate the chromatin changes directly and to test whether similar ANKRD11-sensitive programs operate in human tumor-infiltrating lymphocytes, a necessary step before the findings can inform next-generation cell therapy design.

Subject of Research: Epigenetic regulation of CD8+ T cell dysfunction in chronic viral infection and cancer

Article Title: ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer

Article References: Xu, W., Guo, J., Cao, X., Li, L., Xiao, P., Zhang, X., Jin, Q., Zhang, F., Hou, B., Li, M., & Zhou, X. (2026). ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer. Nature Immunology. https://doi.org/10.1038/s41590-026-02652-x

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02652-x

Keywords: ANKRD11, CD8+ T cells, T cell exhaustion, chronic hepatitis B, epigenetics, immunotherapy, CRISPR screen, AP-1 transcription factors, granzyme B, immune checkpoint blockade, tumor immunity, T cell receptor